Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters
Language
Document Type
Year range
1.
Acquired Hemophilia Following COVID-19 and Influenza Vaccination: A Systematic Review
Parmar, Kanak, Singh, Shivam, Tijani, Lukman, Garcia, David A..
Blood ; 140:5608-5609, 2022.
Article in English | ScienceDirect | ID: covidwho-2120274
2.
In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
Bikdeli, Behnood; Garcia, David A.
Ann Intern Med ; 175(2): JC17, 2022 02.
Article in English | MEDLINE | ID: covidwho-1716078

ABSTRACT

SOURCE CITATION: Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181:1612-20. 34617959.


Subject(s)
COVID-19 , Venous Thromboembolism , Anticoagulants/adverse effects , Heparin/adverse effects , Humans , Inpatients , SARS-CoV-2 , Venous Thromboembolism/chemically induced
3.
In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
Bikdeli, Behnood; Garcia, David A.
Ann Intern Med ; 175(2): JC16, 2022 02.
Article in English | MEDLINE | ID: covidwho-1708592

ABSTRACT

SOURCE CITATION: Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. 34649864.


Subject(s)
COVID-19 , Heparin , Anticoagulants/adverse effects , Heparin/adverse effects , Hospitalization , Humans , Intensive Care Units , SARS-CoV-2
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL